1
Kevin Rodzinak
DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J: Modulateurs allostériques positifs de mglur2, Positive allosteric modulators of mglur2. Merck Sharp & Dohme, DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J, February 16, 2012: WO/2012/021382 (19 worldwide citation)

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involve ...


2
ARRINGTON Kenneth L, DUDKIN Vadim, LAYTON Mark E, PERO Joseph E, REIF Alexander J: Modulateurs allostériques positifs de mglur2, Positive allosteric modulators of mglur2. Merck Sharp & Dohme, ARRINGTON Kenneth L, DUDKIN Vadim, LAYTON Mark E, PERO Joseph E, REIF Alexander J, December 15, 2011: WO/2011/156245 (17 worldwide citation)

The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseas ...


3
BUNDA Jaime L, COX Christopher D, DUDKIN Vadim Y, FIJI Hannah D, KELLY Michael J III, LAYTON Mark E, PERO Joseph E, SHIPE William D, STEEN Justin T: COMPOSÉS DISOINDOLINONE UTILES COMME INHIBITEURS DE PDE 10, ISOINDOLINONE PDE10 INHIBITORS. MERCK SHARP & DOHME, BUNDA Jaime L, COX Christopher D, DUDKIN Vadim Y, FIJI Hannah D, KELLY Michael J III, LAYTON Mark E, PERO Joseph E, SHIPE William D, STEEN Justin T, May 3, 2012: WO/2012/058133 (6 worldwide citation)

The present invention is directed to isoindolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychi ...


4

5
FIJI Hannah D, KELLY Michael J III, KERN Jeffrey C, LAYTON Mark E, PERO Joseph E, REIF Alexander J, ROSSI Michael A: DÉRIVÉS DIMIDAZOPYRIDIN-2-ONE, IMIDAZOPYRIDIN-2-ONE DERIVATIVES. MERCK SHARP & DOHME, FIJI Hannah D, KELLY Michael J III, KERN Jeffrey C, LAYTON Mark E, PERO Joseph E, REIF Alexander J, ROSSI Michael A, December 20, 2012: WO/2012/174199 (1 worldwide citation)

The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and ...



Click the thumbnails below to visualize the patent trend.